Minerva Neurosciences (NASDAQ:NERV – Get Free Report) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued on Wednesday,Zacks.com reports.
Several other analysts also recently commented on NERV. Citizens Jmp assumed coverage on shares of Minerva Neurosciences in a report on Wednesday, April 15th. They issued a “market outperform” rating and a $14.00 target price for the company. Wall Street Zen upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $10.50.
Read Our Latest Stock Analysis on Minerva Neurosciences
Minerva Neurosciences Stock Performance
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. On average, analysts predict that Minerva Neurosciences will post -0.5 EPS for the current year.
Institutional Investors Weigh In On Minerva Neurosciences
A number of hedge funds have recently made changes to their positions in NERV. Bank of New York Mellon Corp purchased a new position in shares of Minerva Neurosciences in the 2nd quarter worth about $419,000. Seven Fleet Capital Management LP bought a new position in Minerva Neurosciences during the first quarter valued at about $6,855,000. DV Trading LLC purchased a new stake in Minerva Neurosciences during the first quarter worth about $5,358,000. Bank of America Corp DE increased its holdings in Minerva Neurosciences by 78,272.5% during the first quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 39,919 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in Minerva Neurosciences by 47,614.0% in the first quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company’s stock worth $25,873,000 after acquiring an additional 4,285,259 shares during the period. 34.56% of the stock is currently owned by institutional investors.
Key Stories Impacting Minerva Neurosciences
Here are the key news stories impacting Minerva Neurosciences this week:
- Positive Sentiment: HC Wainwright’s longer-term projections remain optimistic, calling for positive EPS of $0.64 in fiscal 2029 and $1.67 in fiscal 2030. This indicates the firm still sees potential for meaningful profitability if Minerva’s development programs and commercialization plans succeed.
- Neutral Sentiment: The analyst forecasts EPS of negative $0.15 for fiscal 2028, followed by a return to profitability in 2029. The estimates imply that investors may need to look several years ahead for earnings growth.
- Negative Sentiment: HC Wainwright cut its fiscal 2026 EPS estimate to negative $0.50 from negative $0.20 and reduced its Q3 2026 estimate to negative $0.14 from negative $0.01. The firm also expects Q4 2026 EPS of negative $0.09, compared with its previous estimate of negative $0.01.
- Negative Sentiment: Forecasts for fiscal 2027 were sharply lowered to negative $0.42 per share from positive $4.82. Quarterly 2027 estimates were also reset to approximately negative $0.11 per share, including Q2, Q3 and Q4, signaling substantially weaker near-term earnings expectations.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.
The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.
Featured Articles
- Five stocks we like better than Minerva Neurosciences
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
